×

Register now for access to the Parexel Biotech Content Hub

First Name
Last Name
Company Name
Job Title
Country
Thank you!
Error - something went wrong!
   

Challenging Conventional Patient Recruitment and Care Strategies for Orphan Disease Studies

August 22, 2017

Medicines for rare diseases accounted for 41% of new FDA-approved drugs in 2016.  However, developing new treatments for orphan indications is hugely challenging.

Two of the greatest difficulties consist of finding and recruiting enough subjects to support statistically valid clinical trials and properly and ethically caring for trial patients suffering the quality-of-life (QoL) issues these diseases engender. In this article, Tom Ruane, Senior Director, Patient Recruitment discusses how PAREXEL challenges conventional patient recruitment methods and care strategies to successfully recruit patients for these important studies.

Previous Flipbook
Medical Writing Solutions
Medical Writing Solutions

Parexel's newly enhanced Medical Writing Solutions can help you optimize and better manage the development ...

Next Flipbook
Global Data Operations Overview Brochure
Global Data Operations Overview Brochure

×

Speak to a Parexel® Biotech expert today!

First Name
Last Name
Job Title
Company Name
Country
Tell us how we can help
Thank you!
Error - something went wrong!